AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3886724 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 50
Study 3886724 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine
Number of subjects: 50
Study 30953892 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (G‐IPT)
Number of subjects: 60
Study 30953892 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study 29304065 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS (excitatory theta-burst stimulation) over the left DLPFC
Number of subjects: 51
Study 29304065 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS (inhibitory theta-burst stimulation) over the right DLPFC
Number of subjects: 51
Study 29304065 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS (inhibitory theta-burst stimulation) over the left DLPFC
Number of subjects: 51
Study 29304065 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS (excitatory theta-burst stimulation) over the right DLPFC
Number of subjects: 51
Study 29304065 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 51
Study 28202845 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.50 g ALA-DAG
Number of subjects: 38
Study 28202845 — intervention group
Group type: COMPARATOR
Intervention: 1.25 g ALA-DAG
Number of subjects: 38
Study 28202845 — intervention group
Group type: COMPARATOR
Intervention: Control (0.00 g ALA-DAG)
Number of subjects: 38
Study 25445075 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I intervention targeting early adolescents' cognitive biases related to social anxiety (Child-only condition)
Number of subjects: 18
Study 25445075 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I intervention targeting parents' biases associated with intrusive behavior (Parent-only condition)
Number of subjects: 18
Study 25445075 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I intervention targeting both youth and parents' biases in tandem (Combo condition)
Number of subjects: 18
Study 23093337 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dietary potassium alkali supplementation
Number of subjects: 266
Study 23093337 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dietary potassium alkali supplementation
Number of subjects: 266
Study 23093337 — intervention group
Group type: COMPARATOR
Intervention: Dietary sodium chloride intake
Number of subjects: 266
Study 23093337 — intervention group
Group type: COMPARATOR
Intervention: Dietary potassium intake
Number of subjects: 266
Study 20019087 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarzio (1 microg/kg)
Number of subjects: 24
Study 20019087 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarzio (2.5 microg/kg)
Number of subjects: 24
Study 20019087 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarzio (5 microg/kg)
Number of subjects: 24
Study 20019087 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarzio (10 microg/kg)
Number of subjects: 24
Study 20019087 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarzio (5 microg/kg i.v.)
Number of subjects: 24
Study 20019087 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarzio (300 or 480 microg) in breast cancer patients
Number of subjects: 24
Study 20019087 — intervention group
Group type: COMPARATOR
Intervention: Neupogen (reference product)
Number of subjects: 24
Study 18594001 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/m² pemetrexed (P500)
Number of subjects: 216
Study 18594001 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg/m² pemetrexed (P1000)
Number of subjects: 216
Study 17189542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous conjugated estrogens (EST)
Number of subjects: 12
Study 17189542 — intervention group
Group type: COMPARATOR
Intervention: Saline control (CON)
Number of subjects: 12
Study 12540351 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (two sessions a week for 16 weeks)
Number of subjects: 20
Study 12540351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study 10893361 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick testing (SPT) for Aspergillus fumigatus (AF) as a screening tool and CT scan for diagnosis.
Number of subjects: 255
Study 10893361 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan for diagnosis of ABPA.
Number of subjects: 255
Study 8822241 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐min stroking protocol in addition to a perioral and intraoral stimulation program
Number of subjects: 18
Study 8822241 — intervention group
Group type: COMPARATOR
Intervention: 5‐min stroking protocol (control group)
Number of subjects: 18
Study 1464131 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 20
Study 1464131 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 20
Study 6322985 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (n = 15)
Number of subjects: 31
Study 6322985 — intervention group
Group type: COMPARATOR
Intervention: Self-regulated p.o. diet (control group; n = 16)
Number of subjects: 31
Study 6322985 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to therapy (both groups)
Number of subjects: 31
Study 6322985 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial state (both groups)
Number of subjects: 31
Study 31396667 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (CNN) with data augmentation, trained for 50 epochs, batch size of 8, learning rate of 0.0001, Adadelta optimizer, dropout of 0.20.
Number of subjects: 200
Study 30611996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) administration for 3 months
Number of subjects: 0
Study 28605043 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical Angina (TA)
Number of subjects: 155
Study 28605043 — intervention group
Group type: COMPARATOR
Intervention: Nontypical Angina (NTA)
Number of subjects: 155
Study 24976269 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells (DCs) and IL-2
Number of subjects: 10
Study 24411740 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate weight feedback
Number of subjects: 160
Study 24411740 — intervention group
Group type: COMPARATOR
Intervention: Delayed weight feedback
Number of subjects: 160
Study 22805422 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (QU) supplementation
Number of subjects: 30
Study 22805422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) supplementation
Number of subjects: 30
Study 19238219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP) treatment in symptomatic children
Number of subjects: 112
Study 19238219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP) treatment in asymptomatic infants
Number of subjects: 112
Study 19238219 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular markers examination for drug resistance
Number of subjects: 112
Study 17321391 — intervention group
Group type: EXPERIMENTAL
Intervention: 1CU IOL
Number of subjects: 30
Study 17321391 — intervention group
Group type: COMPARATOR
Intervention: AcrySof MA30 IOL
Number of subjects: 30
Study 17321391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 30
Study 15349013 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release paroxetine (CR)
Number of subjects: 3825
Study 15349013 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release paroxetine (IR)
Number of subjects: 3825
Study 11696462 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD40L concentration in cases (2.86 ng/mL)
Number of subjects: 260
Study 11696462 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD40L concentration above 95th percentile (3.71 ng/mL)
Number of subjects: 260
Study 11696462 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted sCD40L concentration above 95th percentile
Number of subjects: 260
Study 9559206 — intervention group
Group type: EXPERIMENTAL
Intervention: Four serological tests (Bio-Rad IgA, Bio-Rad IgG, Pyloriset EIA-A for IgA, Pyloriset EIA-G for IgG)
Number of subjects: 89
Study 7870845 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 20
Study 7870845 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (0.5 mg)
Number of subjects: 20
Study 7870845 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 subjects)
Number of subjects: 20
Study 2975951 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Strategy (HDS) - interferon alpha‐N1 5M units m‐2 by continuous i.v. infusion over 24 h, escalating by 5 M units m‐2 day‐1 as tolerated over 10 days, repeated every 28 days.
Number of subjects: 53
Study 2975951 — intervention group
Group type: COMPARATOR
Intervention: Low Dose Strategy (LDS) - fixed dose of 2 M units m‐2 by intramuscular injection daily for 28 days, then daily for 7 days every other week.
Number of subjects: 53
Study 31403361 — intervention group
Group type: EXPERIMENTAL
Intervention: Td vaccine
Number of subjects: 66
Study 31403361 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine and a single dose of Td vaccine
Number of subjects: 66
Study 31403361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (colchicine and a single dose of vitamin B6)
Number of subjects: 66
Study 28733130 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise program (12-week postradiation)
Number of subjects: 59
Study 28733130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 59
Study 28733130 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionation radiation
Number of subjects: 59
Study 28733130 — intervention group
Group type: EXPERIMENTAL
Intervention: Median grip strength of study participants
Number of subjects: 59
Study 28498183 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based peer support
Number of subjects: 1269
Study 28498183 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based peer support
Number of subjects: 1269
Study 28498183 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1269
Study 26719545 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 103
Study 26719545 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia (vertical infraclavicular block)
Number of subjects: 103
Study 23103783 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium chloride injection (pain condition)
Number of subjects: 13
Study 23103783 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection (sham condition)
Number of subjects: 13
Study 23103783 — intervention group
Group type: COMPARATOR
Intervention: No injection (control condition)
Number of subjects: 13
Study 21969643 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram plus placebo
Number of subjects: 600
Study 21969643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release plus escitalopram
Number of subjects: 600
Study 21969643 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release plus mirtazapine
Number of subjects: 600
Study 21969643 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care
Number of subjects: 600
Study 21969643 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 600
Study 19820137 — intervention group
Group type: COMPARATOR
Intervention: Plasma levels of Bb and SC5b-9 on day of enrollment
Number of subjects: 17
Study 19820137 — intervention group
Group type: COMPARATOR
Intervention: Plasma levels of Bb and SC5b-9 on day 28 after discharge
Number of subjects: 17
Study 19820137 — intervention group
Group type: COMPARATOR
Intervention: Correlation of circulating levels of complement pathway fragments with severity of renal injury
Number of subjects: 17
Study 19820137 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of the alternative pathway of complement
Number of subjects: 17
Study 16849382 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of ropivacaine 2 mg/ml with fentanyl 2 microg/ml at 10 ml/h
Number of subjects: 40
Study 16849382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly boluses of 10 ml of ropivacaine 2 mg/ml with fentanyl 2 microg/ml
Number of subjects: 40
Study 16849382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent administration
Number of subjects: 40
Study 14519623 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/m2/day rhAngiostatin
Number of subjects: 24
Study 14519623 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/m2/day rhAngiostatin
Number of subjects: 24
Study 14519623 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/m2/day rhAngiostatin
Number of subjects: 24
Study 14519623 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAngiostatin treatment
Number of subjects: 24
Study 10773178 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 9085397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch plus brief physician counseling
Number of subjects: 0
Study 9085397 — intervention group
Group type: COMPARATOR
Intervention: Brief physician counseling alone
Number of subjects: 0
Study 8449586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg daily
Number of subjects: 0
Study 2944997 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg
Number of subjects: 137
Study 2944997 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg
Number of subjects: 137
Study 2944997 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac 100 mg
Number of subjects: 137
Study 2944997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 31954680 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1905
Study 31954680 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1905
Study 31954680 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat revascularization (after both PCI and CABG)
Number of subjects: 1905
Study 31655834 — intervention group
Group type: EXPERIMENTAL
Intervention: 4mg intramuscular dexamethasone immediately after anesthesia
Number of subjects: 19
Study 31655834 — intervention group
Group type: COMPARATOR
Intervention: 90mg etoricoxib 1 hour prior to the procedure
Number of subjects: 19
Study 28822719 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200mg QD for 3 weeks
Number of subjects: 30
Study 28822719 — intervention group
Group type: COMPARATOR
Intervention: Control (no thalidomide)
Number of subjects: 30
Study 26656025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (U-TURN)
Number of subjects: 0
Study 26656025 — intervention group
Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 0
Study 23188075 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (0.1 mg/kg) orally for 8 weeks
Number of subjects: 14
Study 23188075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20809092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost containment measures (12 of 16 interventions analyzed)
Number of subjects: 0
Study 20809092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost containment measures (4 effective interventions)
Number of subjects: 0
Study 18840107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (800 mg)
Number of subjects: 60
Study 18840107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17175822 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine at 20 degrees C
Number of subjects: 20
Study 17175822 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine at 4 degrees C
Number of subjects: 20
Study 14638544 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 6 weeks (Group 1)
Number of subjects: 46
Study 14638544 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (Group 1)
Number of subjects: 46
Study 14638544 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (Group 2)
Number of subjects: 46
Study 14638544 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in Group 2
Number of subjects: 46
Study 10708469 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal 3-dimensional echocardiography (3DE)
Number of subjects: 20
Study 10708469 — intervention group
Group type: COMPARATOR
Intervention: M-mode echocardiography
Number of subjects: 20
Study 10708469 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 20
Study 8775119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice water‐filled CryoCuff
Number of subjects: 71
Study 8775119 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature water in CryoCuff
Number of subjects: 71
Study 8775119 — intervention group
Group type: COMPARATOR
Intervention: No CryoCuff
Number of subjects: 71
Study 1486386 — intervention group
Group type: COMPARATOR
Intervention: Saline washout
Number of subjects: 25
Study 1486386 — intervention group
Group type: EXPERIMENTAL
Intervention: Suby G washout
Number of subjects: 25
Study 1486386 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution R washout
Number of subjects: 25
Study 1486386 — intervention group
Group type: EXPERIMENTAL
Intervention: Returned acidic washout fluid
Number of subjects: 25
Study 1486386 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter encrustation
Number of subjects: 25
Study 6721446 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg and 40 mg)
Number of subjects: 5
Study 6721446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30637839 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT‐IORT
Number of subjects: 332
Study 30637839 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 332
Study 30637839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment group
Number of subjects: 332
Study 30637839 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment group
Number of subjects: 332
Study 29265769 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (measured objectively)
Number of subjects: 124
Study 29265769 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time in inactive individuals (< 150 min/wk of MVPA)
Number of subjects: 124
Study 26349047 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with optimal load
Number of subjects: 21
Study 26349047 — intervention group
Group type: COMPARATOR
Intervention: Training with load 10% below optimal load
Number of subjects: 21
Study 25306897 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-teachers
Number of subjects: 198
Study 25306897 — intervention group
Group type: COMPARATOR
Intervention: Clinicians
Number of subjects: 198
Study 25306897 — intervention group
Group type: COMPARATOR
Intervention: Non-clinical staff
Number of subjects: 198
Study 22429404 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus a self‐regulation based physical activity program (4‐STEPS)
Number of subjects: 0
Study 22429404 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 0
Study 20082754 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng Powder (10 days treatment)
Number of subjects: 60
Study 20082754 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study 20082754 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng Powder
Number of subjects: 60
Study 20082754 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 20082754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 17418536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training with therapists practicing Zen meditation (MFG, n=58)
Number of subjects: 196
Study 17418536 — intervention group
Group type: COMPARATOR
Intervention: Control group without mindfulness training (CG, n=55)
Number of subjects: 196
Study 16250192 — intervention group
Group type: EXPERIMENTAL
Intervention: ETMS use twice every weekday in 35‐min increments during an eight‐week period
Number of subjects: 12
Study 16250192 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme
Number of subjects: 12
Study 16250192 — intervention group
Group type: EXPERIMENTAL
Intervention: ETMS/home exercise programme
Number of subjects: 12
Study 16250192 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme followed by ETMS
Number of subjects: 12
Study 12537632 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice a day for 3 days)
Number of subjects: 0
Study 12537632 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B(1), B(6) and B(12) tablets
Number of subjects: 0
Study 11493043 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention
Number of subjects: 535
Study 9625319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1 g/day)
Number of subjects: 0
Study 7932948 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation of muscle (EMS) using a 'Complex-type' stimulator with flexible elastomer electrodes, current pulses of 200 microseconds at 70 Hz, contraction duration of 5 s, rest duration of 15 s, 10 min per session, three sessions per week for 4 weeks.
Number of subjects: 12
Study 7932948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMS training)
Number of subjects: 12
Study 2467117 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (starting dose 2.5 mg, titrated to 5.0 mg and 10.0 mg at 2-week intervals)
Number of subjects: 0
Study 2467117 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (starting dose 50 mg, titrated to 100 mg after 4 weeks)
Number of subjects: 0
Study 2467117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29326129 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm (random forest model)
Number of subjects: 595
Study 29326129 — intervention group
Group type: COMPARATOR
Intervention: Bundle branch block morphology and QRS duration
Number of subjects: 595
Study 28069054 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-species probiotic
Number of subjects: 60
Study 28069054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60